Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Emerg Infect Dis ; 27(8): 2215-2218, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34287130

RESUMO

We describe a case of endogenous endophthalmitis caused by sequence type 66-K2 hypervirulent Klebsiella pneumoniae in a diabetic patient with no travel history outside the United States. Genomic analysis showed the pathogen has remained highly conserved, retaining >98% genetic similarity to the original strain described in Indonesia in 1935.


Assuntos
Endoftalmite , Infecções por Klebsiella , Endoftalmite/diagnóstico , Endoftalmite/epidemiologia , Humanos , Indonésia , Infecções por Klebsiella/diagnóstico , Klebsiella pneumoniae/genética , Estados Unidos/epidemiologia , Fatores de Virulência
2.
Emerg Infect Dis ; 27(4): 1223-1227, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33755003

RESUMO

Candida auris is an emerging multidrug-resistant yeast. We describe an ongoing C. auris outbreak that began in October 2019 in Los Angeles, California, USA. We used genomic analysis to determine that isolates from 5 of 6 patients belonged to clade III; 4 isolates were closely related.


Assuntos
Candida , Candidíase , Antifúngicos , Genômica , Humanos , Los Angeles , Testes de Sensibilidade Microbiana
3.
Antimicrob Agents Chemother ; 59(10): 6605-7, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26195508

RESUMO

Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-ß-lactam ß-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 µg/ml) from a patient with no prior treatment with ceftazidime-avibactam.


Assuntos
Compostos Azabicíclicos/farmacologia , Proteínas de Bactérias/metabolismo , Ceftazidima/farmacologia , Farmacorresistência Bacteriana , Klebsiella pneumoniae/enzimologia , Inibidores de beta-Lactamases/farmacologia , beta-Lactamases/metabolismo , Klebsiella pneumoniae/efeitos dos fármacos , Testes de Sensibilidade Microbiana
4.
Int J Syst Evol Microbiol ; 62(Pt 8): 1766-1771, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21948093

RESUMO

Legionella-like bacteria were isolated from the respiratory tract of two patients in California, USA, and South Australia, but were not thought to cause disease. These bacteria, strains F2632 and IMVS-3376(T), were found to have identical Legionella macrophage infectivity potentiator (mip) gene sequences and were therefore further characterized to determine their genetic and phenotypic relatedness and properties. Both of these Gram-negative-staining bacterial strains grew on buffered charcoal yeast extract medium, were cysteine auxotrophs and made a characteristic diffusible bright yellow fluorescent pigment, with one strain making a late appearing colony-bound blue-white fluorescent pigment. The optimal in vitro growth temperature was 35 °C, with very poor growth at 37 °C in broth or on solid media. There was no growth in human A549 cells at either 35 or 37 °C, but excellent growth in Acanthamoeba castellani at 30 °C and poorer growth at 35 °C. Phylogenetic analysis of these bacteria was performed by sequence analysis of 16S rRNA, mip, ribonuclease P, ribosomal polymerase B and zinc metalloprotease genes. These studies confirmed that the new strains represented a single novel species of the genus Legionella for which the name Legionella steelei sp. nov. is proposed. The type strain is IMVS-3376(T) ( = IMVS 3113(T) = ATCC BAA-2169(T)).


Assuntos
Legionella/classificação , Legionella/isolamento & purificação , Filogenia , Sistema Respiratório/microbiologia , Adulto , California , Linhagem Celular , DNA Bacteriano/genética , Genótipo , Humanos , Legionella/genética , Masculino , Dados de Sequência Molecular , Pigmentação , RNA Ribossômico 16S/genética , Análise de Sequência de DNA , Austrália do Sul , Temperatura
5.
Am J Clin Pathol ; 157(2): 257-265, 2022 Feb 03.
Artigo em Inglês | MEDLINE | ID: mdl-34542575

RESUMO

OBJECTIVES: Cefiderocol is a novel siderophore cephalosporin with in vitro activity against multidrug-resistant (MDR), gram-negative bacteria and intrinsic structural stability to all classes of carbapenemases. We sought to identify gene variants that could affect the mechanism of action (MOA) of cefiderocol. METHODS: We report a case of bacteremia in a liver transplant candidate with a strain of carbapenem-resistant Escherichia coli that was found to be resistant to cefiderocol despite no prior treatment with this antimicrobial agent. Using whole-genome sequencing, we characterized the genomic content of this E coli isolate and assessed for genetic variants between related strains that were found to be cefiderocol susceptible. RESULTS: We identified several variants in genes with the potential to affect the mechanism of action of cefiderocol. CONCLUSIONS: The cefiderocol resistance in the E coli isolate identified in this study is likely due to mutations in the cirA gene, an iron transporter gene.


Assuntos
Antibacterianos , Escherichia coli , Antibacterianos/farmacologia , Cefalosporinas/farmacologia , Escherichia coli/genética , Genômica , Humanos , Testes de Sensibilidade Microbiana , Cefiderocol
6.
J Clin Microbiol ; 49(1): 452-4, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-20980563

RESUMO

We report the first pediatric case of enteric fever caused by Salmonella enterica serotypes Typhi and Paratyphi A. Mixed infections are infrequently reported, potentially because detection of two different Salmonella serotypes in blood cultures is technically challenging. We suggest laboratory strategies to aid in the recognition of mixed infections.


Assuntos
Antibacterianos/uso terapêutico , Salmonella paratyphi A/isolamento & purificação , Salmonella typhi/isolamento & purificação , Viagem , Febre Tifoide/diagnóstico , Febre Tifoide/microbiologia , Antibacterianos/farmacologia , Sangue/microbiologia , Criança , Humanos , Masculino , Testes de Sensibilidade Microbiana , Febre Tifoide/tratamento farmacológico
7.
J Clin Microbiol ; 49(4): 1667-70, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21325558

RESUMO

The spread of antimicrobial resistance among Enterobacteriaceae is a significant clinical threat. We report the first case of an Enterobacteriaceae strain harboring the NDM-1 metallo-ß-lactamase in a pediatric patient in the United States. We describe strategies for the detection of this novel resistance mechanism encountered in an isolate of Klebsiella pneumoniae.


Assuntos
Infecções por Klebsiella/microbiologia , Klebsiella pneumoniae/enzimologia , Klebsiella pneumoniae/isolamento & purificação , beta-Lactamases/biossíntese , Antibacterianos/farmacologia , Humanos , Lactente , Masculino , Testes de Sensibilidade Microbiana/métodos , Estados Unidos
9.
IDCases ; 20: e00781, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32420029

RESUMO

We describe a case of carbapenem resistant E. coli isolated from urine in an 87-year-old woman with recurrent urinary tract infections. Using whole genome sequencing (WGS), we identified the carbapenem resistance mechanism to be a combination of ompC porin loss and plasmid-mediated AmpC gene blaCMY-2 , which was not detected by routine molecular and phenotypic carbapenemase assays. Our case raises a concern for the limitation of current CRE screening tools for emerging resistance mechanisms and demonstrates the utility of WGS as a better tool for characterization of CRE in the clinical setting.

10.
J Med Microbiol ; 59(Pt 11): 1383-1386, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20688947

RESUMO

The spread of antimicrobial resistance among members of the Enterobacteriaceae is a significant clinical threat. We report the treatment of pan-resistant Klebsiella pneumoniae bacteraemia with combination tigecycline and colistin in a 49-year-old male and review available therapeutic options. Despite a poor prognosis, the patient recovered, but remains colonized with the pan-resistant isolate.


Assuntos
Antibacterianos/administração & dosagem , Bacteriemia/complicações , Colistina/administração & dosagem , Infecções por Klebsiella/complicações , Klebsiella pneumoniae/isolamento & purificação , Minociclina/análogos & derivados , Pneumonia Bacteriana/complicações , Animais , Antibacterianos/farmacologia , Bacteriemia/diagnóstico , Bacteriemia/tratamento farmacológico , Farmacorresistência Bacteriana Múltipla , Quimioterapia Combinada/métodos , Humanos , Infecções por Klebsiella/diagnóstico , Infecções por Klebsiella/tratamento farmacológico , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Minociclina/administração & dosagem , Pneumonia Bacteriana/diagnóstico , Pneumonia Bacteriana/tratamento farmacológico , Tigeciclina
11.
J Clin Microbiol ; 44(11): 3883-6, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16957043

RESUMO

Staphylococcus aureus is one of the most commonly isolated organisms in nosocomial infections. While the prevalence of methicillin-resistant S. aureus (MRSA) continues to increase worldwide, there is concern about an increase in vancomycin MICs among S. aureus strains. The prevalence of MRSA and vancomycin MIC trends in S. aureus from patients in a university hospital were analyzed. Clinical Laboratory Standards Institute (CLSI, formerly NCCLS) reference broth microdilution MIC testing was performed on all clinically relevant S. aureus isolates from January 2000 through December 2004. A total of 6,003 S. aureus isolates were analyzed. No vancomycin-resistant S. aureus isolates were detected. One MRSA isolate had a vancomycin MIC of 8 mug/ml and was confirmed as vancomycin-intermediate S. aureus. Among the 6,002 remaining isolates, a shift in vancomycin MICs from

Assuntos
Antibacterianos/farmacologia , Staphylococcus aureus/efeitos dos fármacos , Vancomicina/farmacologia , Hospitais Universitários , Humanos , Resistência a Meticilina , Testes de Sensibilidade Microbiana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA